Radioligand Therapy Targets in Melanoma
We screened every cell-surface protein with tumor immunohistochemistry data in melanoma (including cutaneous melanoma). 4,342 show detectable protein staining. Established and emerging radioligand targets expressed in melanoma include HER3 (ERBB3), STEAP2, B7-H3 (CD276) and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.
Need a shortlist for your own melanoma program? Rank every candidate against your isotope, organ-dose limits and novelty bar.
Rank melanoma targets freeEstablished and emerging radioligand targets in melanoma
Targets already pursued with radioligands or other targeted modalities that show protein expression in melanoma:
| Target | IHC in melanoma | % positive | Internalizes |
|---|---|---|---|
| HER3 (ERBB3) | High (0.90) | 100% | yes |
| STEAP2 | High (0.79) | 100% | — |
| B7-H3 (CD276) | High (0.69) | 100% | — |
| c-MET (MET) | High (0.67) | 100% | yes |
| ITGAV | High (0.67) | 100% | — |
| TMEFF2 | High (0.58) | 92% | — |
| SSTR2 | Medium (0.39) | 75% | yes |
| FAP | Low (0.19) | 42% | yes |
| Nectin-4 (NECTIN4) | Low (0.08) | 25% | no |
| CD19 | Low (0.06) | 8% | — |
| HER2 (ERBB2) | Low (0.03) | 9% | yes |
| Claudin 18.2 (CLDN18) | Low (0.03) | 8% | uncertain |
| KIT | Low (0.03) | 8% | no |
Top cell-surface targets for melanoma radioligand therapy
A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.
| # | Target | IHC in melanoma | % positive | Internalizes | Clinical stage |
|---|---|---|---|---|---|
| 1 | MST1R macrophage stimulating 1 receptor | High (0.94) | 100% | yes | FDA-Approved |
| 2 | HER3 (ERBB3) erb-b2 receptor tyrosine kinase 3 | High (0.90) | 100% | yes | FDA-Approved |
| 3 | S1PR1 sphingosine-1-phosphate receptor 1 | High (0.69) | 100% | yes | FDA-Approved |
| 4 | c-MET (MET) MET proto-oncogene, receptor tyrosine kinase | High (0.67) | 100% | yes | FDA-Approved |
| 5 | IGF1R insulin like growth factor 1 receptor | High (0.78) | 100% | yes | FDA-Approved |
| 6 | AMFR autocrine motility factor receptor | High (1.00) | 100% | yes | Discovery |
| 7 | NR3C2 nuclear receptor subfamily 3 group C member 2 | High (0.87) | 100% | uncertain | FDA-Approved |
| 8 | RET ret proto-oncogene | High (0.92) | 100% | — | FDA-Approved |
| 9 | GPR139 G protein-coupled receptor 139 | High (0.97) | 100% | yes | Discovery |
| 10 | TRPV2 transient receptor potential cation channel subfamily V member 2 | High (1.00) | 100% | uncertain | Discovery |
| 11 | EPHB2 EPH receptor B2 | High (0.67) | 100% | uncertain | FDA-Approved |
| 12 | HRH4 histamine receptor H4 | High (0.67) | 100% | yes | Clinical |
| 13 | AGTRAP angiotensin II receptor associated protein | High (0.81) | 100% | yes | Discovery |
| 14 | P2RX7 purinergic receptor P2X 7 | High (0.79) | 100% | uncertain | Clinical |
| 15 | FGFR1 fibroblast growth factor receptor 1 | High (0.53) | 90% | yes | FDA-Approved |
| 16 | NOTCH2 notch receptor 2 | High (0.61) | 100% | yes | Clinical |
| 17 | CHRNA7 cholinergic receptor nicotinic alpha 7 subunit | High (0.69) | 83% | yes | Clinical |
| 18 | BRAF B-Raf proto-oncogene, serine/threonine kinase | High (0.97) | 100% | — | FDA-Approved |
| 19 | APH1A aph-1A gamma-secretase subunit | High (0.97) | 100% | — | FDA-Approved |
| 20 | SDCBP syndecan binding protein | High (1.00) | 100% | — | Discovery |
| 21 | CDK2 cyclin dependent kinase 2 | High (0.83) | 100% | — | Clinical |
| 22 | TNFRSF12A TNF receptor superfamily member 12A | High (0.92) | 100% | uncertain | Clinical |
| 23 | GABRE gamma-aminobutyric acid type A receptor subunit epsilon | High (0.81) | 100% | uncertain | FDA-Approved |
| 24 | IL18R1 interleukin 18 receptor 1 | High (0.89) | 100% | uncertain | Clinical |
| 25 | PDE4D phosphodiesterase 4D | High (0.93) | 100% | — | FDA-Approved |
Internalizing receptors in melanoma
Targets expressed in melanoma that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:
MST1R · HER3 (ERBB3) · S1PR1 · c-MET (MET) · IGF1R · AMFR · GPR139 · HRH4 · AGTRAP · FGFR1 · NOTCH2 · CHRNA7
Melanoma targets already in clinical development
Targets with a clinical-stage drug program (any modality) that are also expressed in melanoma. Clinical precedent lowers development risk but usually means more competition:
MST1R · HER3 (ERBB3) · S1PR1 · c-MET (MET) · IGF1R · NR3C2 · RET · EPHB2 · HRH4 · P2RX7 · FGFR1 · NOTCH2
How these melanoma targets are ranked
Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in melanoma, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.
Rank melanoma targets against your own criteria: isotope, organ limits, novelty.
Run a free melanoma analysisRadioligand therapy targets in other cancers
- Prostate Cancer
- Neuroendocrine Tumors
- Lung Cancer
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Kidney Cancer
- Bladder Cancer
- Gastric Cancer
- Liver Cancer
- Glioma
- Head and Neck Cancer
- Thyroid Cancer
- Lymphoma
- Cervical Cancer
- Endometrial Cancer
- Skin Cancer
- Testicular Cancer
Data sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.